BR112020003207A2 - métodos de tratar um sujeito humano sofrendo de ou em risco de desenvolver doença do enxerto versus hospedeiro, hemorragia alveolar difusa e doença veno-oclusiva e de tratar, prevenir ou melhorar um ou mais sintomas neurológicos associados com a doença do enxerto versus hospedeiro ou microangiopatia trombótica associada com transplante de célula-tronco hematopoiética. - Google Patents

métodos de tratar um sujeito humano sofrendo de ou em risco de desenvolver doença do enxerto versus hospedeiro, hemorragia alveolar difusa e doença veno-oclusiva e de tratar, prevenir ou melhorar um ou mais sintomas neurológicos associados com a doença do enxerto versus hospedeiro ou microangiopatia trombótica associada com transplante de célula-tronco hematopoiética. Download PDF

Info

Publication number
BR112020003207A2
BR112020003207A2 BR112020003207-7A BR112020003207A BR112020003207A2 BR 112020003207 A2 BR112020003207 A2 BR 112020003207A2 BR 112020003207 A BR112020003207 A BR 112020003207A BR 112020003207 A2 BR112020003207 A2 BR 112020003207A2
Authority
BR
Brazil
Prior art keywords
masp
antibody
subject
seq
complement
Prior art date
Application number
BR112020003207-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Gregory A. Demopulos
Thomas Dudler
Hans-Wilhelm Schwaeble
Original Assignee
Omeros Corporation
University Of Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corporation, University Of Leicester filed Critical Omeros Corporation
Publication of BR112020003207A2 publication Critical patent/BR112020003207A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Environmental Sciences (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
BR112020003207-7A 2017-08-15 2018-08-14 métodos de tratar um sujeito humano sofrendo de ou em risco de desenvolver doença do enxerto versus hospedeiro, hemorragia alveolar difusa e doença veno-oclusiva e de tratar, prevenir ou melhorar um ou mais sintomas neurológicos associados com a doença do enxerto versus hospedeiro ou microangiopatia trombótica associada com transplante de célula-tronco hematopoiética. BR112020003207A2 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762545864P 2017-08-15 2017-08-15
US62/545,864 2017-08-15
US201762574690P 2017-10-19 2017-10-19
US62/574,690 2017-10-19
US201862630756P 2018-02-14 2018-02-14
US62/630,756 2018-02-14
US201862637281P 2018-03-01 2018-03-01
US62/637,281 2018-03-01
PCT/US2018/046690 WO2019036460A1 (en) 2017-08-15 2018-08-14 METHODS OF TREATING AND / OR PREVENTING HOST GRAFT DISORDER AND / OR DIFFUSE ALVEOLAR HEMORRHAGE AND / OR VENO-OCCLUSIVE DISEASE ASSOCIATED WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION

Publications (1)

Publication Number Publication Date
BR112020003207A2 true BR112020003207A2 (pt) 2020-10-06

Family

ID=65362042

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020003207-7A BR112020003207A2 (pt) 2017-08-15 2018-08-14 métodos de tratar um sujeito humano sofrendo de ou em risco de desenvolver doença do enxerto versus hospedeiro, hemorragia alveolar difusa e doença veno-oclusiva e de tratar, prevenir ou melhorar um ou mais sintomas neurológicos associados com a doença do enxerto versus hospedeiro ou microangiopatia trombótica associada com transplante de célula-tronco hematopoiética.

Country Status (20)

Country Link
US (3) US11013772B2 (https=)
EP (1) EP3668531A4 (https=)
JP (3) JP2020531452A (https=)
KR (3) KR102679441B1 (https=)
CN (3) CN118436776A (https=)
AU (1) AU2018318982B2 (https=)
BR (1) BR112020003207A2 (https=)
CA (1) CA3072940A1 (https=)
CL (3) CL2020000384A1 (https=)
GE (2) GEP20237541B (https=)
IL (3) IL272674B2 (https=)
JO (1) JOP20200021A1 (https=)
MA (1) MA49915A (https=)
MX (3) MX2020001728A (https=)
MY (1) MY210026A (https=)
PH (1) PH12020500276A1 (https=)
SG (1) SG11202001014WA (https=)
TW (3) TWI881481B (https=)
WO (1) WO2019036460A1 (https=)
ZA (1) ZA202407503B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL311042B1 (en) 2018-05-29 2026-04-01 Omeros Corp MASP-2 inhibitors and methods of use
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
MX2022006334A (es) * 2019-11-26 2022-06-22 Omeros Corp Metodos para tratar y/o prevenir el sindrome de neumonia idiopatica (ips) y/o el sindrome de fuga capilar (cls) y/o el sindrome de injerto (es) y/o la sobrecarga de fluidos (fo) asociados con el trasplante de celulas madre hematopoyeticas.
BR112022010895A2 (pt) 2019-12-04 2022-09-06 Omeros Corp Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan
EP4069676A1 (en) 2019-12-04 2022-10-12 Omeros Corporation Masp-2 inhibitors and methods of use
IL293588B1 (en) 2019-12-04 2026-04-01 Omeros Corp 3-Amino-1-methylpyrazin-2(H1)-one derivatives as MASP-2 inhibitors, compositions containing them and uses thereof
EP4069678A1 (en) 2019-12-04 2022-10-12 Omeros Corporation Masp-2 inhibitors and methods of use
CN116322670A (zh) * 2020-07-22 2023-06-23 北京泰德制药股份有限公司 治疗造血干细胞移植后的移植物抗宿主病的方法
CN113057142B (zh) * 2021-03-30 2022-12-09 四川大学华西医院 一种视网膜内和/或视网膜下纤维化动物模型的构建方法
TW202305010A (zh) * 2021-04-25 2023-02-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｍａｓｐ２抗體、其抗原結合片段及醫藥用途
US20230265215A1 (en) 2021-12-10 2023-08-24 Omeros Corporation Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
CN114532982A (zh) * 2022-01-12 2022-05-27 高谋 评价干细胞系统移植调控补体活化作用的体系
CN114686585B (zh) * 2022-04-01 2023-06-30 中国人民解放军总医院 Tmem65在预警和/或治疗高原病中的应用
EP4626891A1 (en) 2022-11-30 2025-10-08 Omeros Corporation Fused pyrimidines as masp-2 inhibitors
US20250122225A1 (en) 2023-10-06 2025-04-17 Omeros Corporation Masp-2 inhibitors and methods of use

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4394370A (en) 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4526909A (en) 1984-01-09 1985-07-02 Regents Of The University Of California Polymethylmethacrylate delivery system for bone morphogenetic protein
US4563489A (en) 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
JPH0662679B2 (ja) 1985-06-21 1994-08-17 新田ゼラチン株式会社 組織親和性コラ−ゲンとその製法
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
MC2115A1 (fr) 1987-12-15 1991-07-05 Gene Shears Pty Ltd Ribozynes
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
EP0438803B1 (en) 1990-01-26 1997-03-12 Immunomedics, Inc. Vaccines against cancer and infectious diseases
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
JPH10510540A (ja) 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
JP2003505427A (ja) 1999-07-21 2003-02-12 オメロス コーポレイション 疼痛、炎症および軟骨分解の抑制のための溶液および方法
US6649592B1 (en) 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
CN1697647A (zh) 2002-02-01 2005-11-16 奥默罗斯公司 用于抑制疼痛,炎症和软骨退化的溶液及方法
ES2601143T3 (es) 2002-07-19 2017-02-14 Omeros Corporation Copolímeros tribloque biodegradables, métodos de síntesis de los mismos, e hidrogeles y biomateriales preparados a partir de los mismos
HUE024996T2 (en) 2003-05-12 2016-01-28 Helion Biotech Aps Anti-MASP-2 antibodies
CN101065148A (zh) * 2003-07-03 2007-10-31 奥索-麦克尼尔药品公司 结合补体级联抑制剂
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP1879610A1 (en) 2005-05-06 2008-01-23 Laboratoires Serono S.A. Use of an immunoglobulin domain-containing cell surface recognition molecule for treating diseases
ES2688589T3 (es) 2010-07-21 2018-11-05 Eastern Virginia Medical School Compuestos peptídicos para regular el sistema del complemento
US9644035B2 (en) * 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20150166676A1 (en) * 2011-04-08 2015-06-18 Omeros Corporation Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
HUE049154T2 (hu) * 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
HK1218300A1 (zh) * 2013-01-23 2017-02-10 Musc Foundation For Research Development 基於天然抗體的靶向結構體及其應用
JP2016539919A (ja) * 2013-10-17 2016-12-22 オメロス コーポレーション Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法
WO2015187992A2 (en) * 2014-06-05 2015-12-10 The Regents Of The University Of Colorado, A Body Corporate Map44 polypeptides and constructs based on natural antibodies and uses thereof
CA2988313A1 (en) * 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
AU2016354117B2 (en) * 2015-11-09 2019-11-28 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation

Also Published As

Publication number Publication date
CN118436776A (zh) 2024-08-06
MX2024012816A (es) 2024-11-08
AU2018318982A2 (en) 2020-03-26
WO2019036460A1 (en) 2019-02-21
IL315726A (en) 2024-11-01
JP2023123627A (ja) 2023-09-05
MY210026A (en) 2025-08-22
TW202529812A (zh) 2025-08-01
MA49915A (fr) 2021-03-24
PH12020500276A1 (en) 2020-09-21
EP3668531A4 (en) 2021-03-24
MX2024012815A (es) 2024-11-08
US11013772B2 (en) 2021-05-25
US20240293465A1 (en) 2024-09-05
IL272674B2 (en) 2025-02-01
CN118634322A (zh) 2024-09-13
JOP20200021A1 (ar) 2020-02-02
AU2018318982B2 (en) 2025-02-20
KR102863808B1 (ko) 2025-09-25
CA3072940A1 (en) 2019-02-21
TWI881481B (zh) 2025-04-21
IL315724A (en) 2024-11-01
KR20250150131A (ko) 2025-10-17
MX2020001728A (es) 2020-09-25
TWI818919B (zh) 2023-10-21
CL2020000384A1 (es) 2020-08-14
ZA202407503B (en) 2025-06-25
JP2025108730A (ja) 2025-07-23
GEAP202315297A (en) 2023-05-10
US20190125802A1 (en) 2019-05-02
JP2020531452A (ja) 2020-11-05
US20210290684A1 (en) 2021-09-23
CN111278449B (zh) 2025-01-07
CL2022000194A1 (es) 2023-01-27
CL2022000195A1 (es) 2023-01-27
IL272674A (en) 2020-03-31
EP3668531A1 (en) 2020-06-24
US11896621B2 (en) 2024-02-13
IL272674B1 (en) 2024-10-01
GEP20237541B (en) 2023-09-25
KR20200040805A (ko) 2020-04-20
KR20240105500A (ko) 2024-07-05
TW201920288A (zh) 2019-06-01
TW202402809A (zh) 2024-01-16
SG11202001014WA (en) 2020-03-30
KR102679441B1 (ko) 2024-07-02
AU2018318982A1 (en) 2020-03-19
CN111278449A (zh) 2020-06-12

Similar Documents

Publication Publication Date Title
US20240124611A1 (en) Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US20240343830A1 (en) Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US20240293465A1 (en) Methods for Treating and/or Preventing Graft-Versus-Host Disease and/or Diffuse Alveolar Hemorrhage and/or Veno-Occlusive Disease Associated with Hematopoietic Stem Cell Transplant
US20240076409A1 (en) Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US20240218080A1 (en) Methods for treating and/or preventing idiopathic pneumonia syndrome (ips) and/or capillary leak syndrome (cls) and/or engraftment syndrome (es) and/or fluid overload (fo) associated with hematopoietic stem cell transplant
EA046178B1 (ru) Способы лечения и/или предотвращения реакции трансплантат против хозяина и/или диффузного альвеолярного кровотечения, и/или веноокклюзионной болезни, связанных с трансплантатом гемопоэтических стволовых клеток
BR112018009311B1 (pt) Uso de uma composição compreendendo uma quantidade de um anticorpo inibidor de masp-2
EA042534B1 (ru) Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]